| 51 |
20407837 | Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. | 2012 Mar |
3 |
| 52 |
22162472 | Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. | 2012 Feb |
1 |
| 53 |
22278424 | Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. | 2012 Apr |
3 |
| 54 |
22362824 | Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. | 2012 May |
1 |
| 55 |
22408123 | GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. | 2012 May |
1 |
| 56 |
23186966 | Diabetic Ketoacidosis in Acromegaly: A Case Report. | 2012 Nov 27 |
1 |
| 57 |
23930065 | A case of an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage. | 2012 Jan |
1 |
| 58 |
21045065 | Hypothesis: Extra-hepatic acromegaly: a new paradigm? | 2011 Jan |
2 |
| 59 |
21104581 | Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. | 2011 Jan |
1 |
| 60 |
21148630 | Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. | 2011 Mar |
3 |
| 61 |
21209237 | Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in asian and Western acromegaly patients. | 2011 Dec |
4 |
| 62 |
21221818 | Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. | 2011 Sep |
3 |
| 63 |
21498100 | GH receptor blocker administration and muscle-tendon collagen synthesis in humans. | 2011 Jun |
1 |
| 64 |
18498055 | Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. | 2010 |
3 |
| 65 |
19850678 | The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. | 2010 Jan |
2 |
| 66 |
20050861 | Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). | 2010 Jul |
2 |
| 67 |
20190543 | Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy. | 2010 |
1 |
| 68 |
20887124 | Pharmacological management of acromegaly: a current perspective. | 2010 Oct |
1 |
| 69 |
19018786 | Long-term experience of pegvisomant therapy as a treatment for acromegaly. | 2009 Jul |
1 |
| 70 |
19067728 | Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD). | 2009 Mar |
4 |
| 71 |
19141604 | Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. | 2009 Apr |
1 |
| 72 |
19147599 | Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. | 2009 Apr |
1 |
| 73 |
19153502 | Pitfalls of insulin-like growth factor I assays. | 2009 Jan |
1 |
| 74 |
19258431 | Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. | 2009 May |
1 |
| 75 |
19366854 | Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. | 2009 Jul |
2 |
| 76 |
19411301 | Successful use of weekly pegvisomant administration in patients with acromegaly. | 2009 Jul |
3 |
| 77 |
19444656 | Current therapy and drug pipeline for the treatment of patients with acromegaly. | 2009 Apr |
1 |
| 78 |
19684052 | ACROSTUDY: the first 5 years. | 2009 Nov |
1 |
| 79 |
19684061 | The German ACROSTUDY: past and present. | 2009 Nov |
1 |
| 80 |
19763127 | Somatostatin analog and pegvisomant combination therapy for acromegaly. | 2009 Oct |
1 |
| 81 |
19814797 | Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. | 2009 Oct 8 |
4 |
| 82 |
20003832 | A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. | 2009 Dec 1 |
2 |
| 83 |
20009494 | Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. | 2009 Dec |
4 |
| 84 |
18031320 | Pegvisomant-primed GH stimulation test. | 2008 Jun |
1 |
| 85 |
18431372 | Long-term effects of pegvisomant in patients with acromegaly. | 2008 Jun |
1 |
| 86 |
18492755 | Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. | 2008 Aug |
1 |
| 87 |
18611977 | Lipodystrophy in patients with acromegaly receiving pegvisomant. | 2008 Sep |
2 |
| 88 |
18617577 | Growth hormone excess and the development of growth hormone receptor antagonists. | 2008 Nov |
1 |
| 89 |
18766168 | Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. | 2008 Aug |
1 |
| 90 |
17077131 | Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. | 2007 Jan |
8 |
| 91 |
17105844 | Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. | 2007 Feb |
1 |
| 92 |
17218728 | Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. | 2007 Jan |
1 |
| 93 |
17289896 | Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. | 2007 Feb 1 |
4 |
| 94 |
17341562 | The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. | 2007 May |
2 |
| 95 |
17427111 | Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. | 2007 Mar |
2 |
| 96 |
17431794 | Serum IGF-I levels in the diagnosis and monitoring of acromegaly. | 2007 |
1 |
| 97 |
17534717 | Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. | 2007 |
2 |
| 98 |
17982395 | McCune-Albright syndrome in adulthood. | 2007 Aug |
1 |
| 99 |
18058730 | The medical treatment of acromegaly. | 2007 Jul-Aug |
2 |
| 100 |
18058736 | [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly]. | 2007 Sep-Oct |
2 |